BTL ExoMind
Transcranial magnetic stimulation
Classification & configurations
Category group: Adjacent & Wellness Equipment
At a glance
- New price
- Not published
- FDA status
- Supplies & recurring costs
- Supply details not yet documented.
Sources and verified data on file
Data on file
- Recurring consumables
- Not verified
- FDA
- FDA ClearedK260691
- Used asking prices
- Not verified
- This panel shows a per-treatment supply cost only when a recorded figure has a dated source.
- Bottle prices and estimates may still appear under Treatment & running costs.
- The calculator may include a labeled planning estimate. Review it or enter your own allowance; missing data never means $0.
Figures are reference points, not current offers.
Read FDA-cleared indicationsExact wording from 1 FDA record
K260691 (BTL Industries, Inc., 2026)
The BTL-699 is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. The BTL-699 is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD). The BTL-699 is indicated as an adjunct for the treatment of Major Depressive Disorder in adolescent patients (age 15-21).
Verbatim from the FDA 510(k) summary, retrieved 18 Sep 2026.
Page updated: September 21, 2026 · How we verify
New-equipment price not yet documented
For a complete budget, ask for an itemized quote covering the device, accessories, training and service.
Price sourcesSources, dates and configurations
No price sources are documented yet. Ask the seller for a current, itemized quote.
Key factsCompany, specifications and verification dates
| Manufacturer | BTL Industries |
|---|---|
| Company | Owner: BTL Group; founder-controlled (private) (family / founder owned, since 1993) · Distribution: direct |
| Parent company | Not published |
| Brand owner | BTL Industries |
| Category | Transcranial magnetic stimulation |
| Technology | Not published |
| FDA status | FDA Cleared |
| 510(k) citation | K260691 |
| New price range | Not published |
| Used asking range | Not published |
| Consumables | Not published |
| Launch year | Not published |
| Pricing | Not published |
| Manufacturer-source documents checked | Not published |
Overview
A prescription-only transcranial magnetic stimulation system. It is not an aesthetic treatment device.
The FDA record is reproduced on this page as written; nothing further is stated about it here.
FDA & regulatory detailClearance timeline, authorization route and citation notes
Cleared as BTL-699. Decision date 2026-08-23. Regulations 21 CFR 882.5805 and 882.5802; product codes OBP and QCI; reviewed by the Neurology panel; Class II; prescription use only. Common name: Repetitive Transcranial Magnetic Stimulation (rTMS) System.
FDA-cleared indications (verbatim)
K260691 (BTL Industries, Inc., 2026)
The BTL-699 is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. The BTL-699 is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD). The BTL-699 is indicated as an adjunct for the treatment of Major Depressive Disorder in adolescent patients (age 15-21).
Verbatim from the FDA 510(k) summary, retrieved 18 Sep 2026.
Applicant on the FDA record
BTL Industries, Inc.The applicant named on the FDA record can differ from the brand shown on the device.
Regulatory data comes from public FDA records and may lag recent updates. Confirm the applicable status and documentation before purchase.
Treatment & running costs
Treatments
Sessions & timing
No treatment schedule documented yet.
What practices charge
No sourced treatment price on file.
Supplies & recurring costs
Consumable costs are not documented yet.
Annual service & support
No annual service cost documented yet.
Warranty & serviceWhat to confirm in writing before you buy
Before buying new or used, confirm in writing:
- Current warranty coverage
- Included training
- Service terms
Chains using this device
A chain listing does not establish availability at every location.
No confirmed chain deployments recorded yet.
Owner & operator reviews
Write a reviewNo owner or operator reviews yet. Be the first →
Current alternatives
Current catalog models to research. Confirm availability and configuration with the supplier.
No current alternatives identified in the catalog yet. Browse current models
History4 tracked changes
Every tracked change to pricing, lifecycle status, FDA data and warranty terms — newest first.
September 21, 2026
Availability status
Current
Source: Catalog update
September 21, 2026
Lifecycle status
Current
Filled the missing catalog status from BTL’s US product page and equipment inquiry option. Prescription-only positioning, FDA information, indication and category are unchanged. Current is not a stock guarantee or a treatment recommendation.
Source: https://bodybybtl.com/solutions/exomind; https://bodybybtl.com/request-info
September 18, 2026
fda ifu
September 18, 2026: Astra visually transcribed the Indications for Use block from FDA PDF page 4. Original wording retained, including source spelling; line wrapping/bullet glyphs normalized. Replaces incomplete text (K221571) or summary wording with the indication-form wording (K260691). Model-to-clearance associations were not reclassified by this transcription check.
Source: https://www.accessdata.fda.gov/cdrh_docs/pdf26/K260691.pdf
September 18, 2026
Company profile link
Not linked → BTL Aesthetics
Linked ExoMind to the existing BTL company record. The official US EXOMIND page identifies BTL Industries, Inc. and links the international BTL Aesthetics site. Original manufacturer wording retained; claim status remains unclaimed.
Source: https://bodybybtl.com/solutions/exomind
Cite this data: The Aesthetic Index, "BTL ExoMind — pricing, FDA status and cost to own", aestheticindex.co (accessed September 25, 2026).
Get the full State of Aesthetic Devices 2026 report
A catalog of US-marketed aesthetic and wellness devices — preview it free.
Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.